Skip to main content

Table 1 Patient demographics and management of PE

From: Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: case series

No.

1

2

3

4

Age

7 months

2 years 8 months

3 years

5 months

Sex

Male

Female

Male

Male

Height (cm)

72

92

89

64

Weight (kg)

8.8

15.6

14.7

6.4

Comorbidity

None

None

None

None

Total dose of IVIG (g/kg)

3

4

4

4

The day on which PE started

Day 10

Day 9

Day 9

Day 8

EF before PE (%)

75

63

70

69

Coronary artery lesions

 Before PE

None

Dilation

None

None

 After PE

None

Dilation

Dilation

None

Sedation during PE

DEX (μg/kg/h)

0.4–0.7

0.4–0.6

0.4–0.7

0.2–0.7

Respiratory management

0.5 L/min

RA

RA

6 L/min

PE duration (days)

3

3

5

5

Transfusion

 RBC

60 mL

None

240 mL

90 mL

 FFP

None

None

None

320 mL

Length of hospital stay (days)

6

15

14

16

Hemorrhagic complications

None

None

None

None

Other complications

None

None

None

None

  1. IVIG intravenous immunoglobulin therapy, PE plasma exchange, EF light ventricular ejection fraction, DEX dexmedetomidine, RA room air, RBC red blood cell concentration, FFP fresh frozen plasma